The Bachem Group, one of the world’s leading manufacturers of peptides and oligonucleotides, has recently signed a CHF 1 billion peptide supply contract. The contract extends over five years and will allow the company to expand capacity at all its sites, including its plant in Vionnaz, in the canton of Valais.
Bachem announced the signing of a new work mandate for the delivery of large volumes of peptides for a minimum total of CHF 1 billion over a five-year period from 2025 to 2029.
Thomas Meier, CEO of Bachem, said, “We are very pleased with this follow-up order and the renewed confidence in our work. Long-term collaborations are important for us and our partners: they allow us to reliably plan the development and utilization of production capacities. The revenues from this collaboration will help us achieve our growth objectives and strengthen our leadership in the peptide market.”
Bachem is pursuing an investment program at all sites to increase capacity. A modern, large-scale peptide and oligonucleotide manufacturing facility with the potential to double production capacity at the Bubendorf site. A new site in Switzerland is planned in Eiken (canton of Aargau) and aims to further strengthen the production network from the end of the decade. Bachem is also investing in expanding the capacity of its global manufacturing network at sites in Vionnaz (Switzerland), Torrance (USA), Vista (USA) and St. Helens (UK).
The canton of Valais, a global hub for chemical and pharmaceutical companies
The canton of Valais is an attractive location for chemical companies for many reasons. It offers access to abundant and affordable hydropower, ideal for powering chemical manufacturing processes. This has been a major attraction for pharmaceutical and chemical companies since the beginning of the 20th century and has led to the creation of several international groups in the region, such as Bachem.
Bachem in a few words…
Founded in 1971, the Swiss biotechnology company specializing in the development and manufacture of peptides and oligonucleotides, Bachem, operates worldwide, with manufacturing facilities in Switzerland, the United States and the United Kingdom. Bachem’s core business is the custom synthesis of peptides, including modified and labeled peptides, and active pharmaceutical ingredients (APIs).
Bachem’s site in Vionnaz (canton of Valais) was founded in 1973 and acquired by Bachem in 2001. On this GMP site, small organic molecules and generic APIs are produced. Bachem Vionnaz develops amino acid chemistry, electrochemistry, enzymatic reactions, chiral synthesis, pyrogen-free production and high temperature reactions.
Source and photo credit: Bachem